SEC Form 4 · accession 0001562180-16-003919
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas A Saccomano
Officer — CSO
Period of report
Dec 27, 2016
Accepted (ET)
Dec 29, 2016 · 5:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | $0.00 | Dec 27, 2016 | A | 21,875 | A | — | Dec 28, 2020 | Common Stock | 21,875 | 21,875 | D |
| Stock Option (Right to Buy)F2 | $8.79 | Dec 27, 2016 | A | 131,250 | A | — | Dec 27, 2026 | Common Stock | 131,250 | 131,250 | D |
Explanation of responses
- F1Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2017.
- F2The option vests in four equal annual installments beginning on December 16, 2017.